SCHEMBL7174833

SCHEMBL7174833

Cc1cc(C)c(C(=O)[PH](=O)c2c(Cl)c(Cl)c(C(=O)c3ccccc3)c(Cl)c2Cl)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.39
MEN1 O00255 3/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MCOLN3 Q8TDD5 1/20 0.37
ALOX15 P16050 1/20 0.35
BCL2L1 Q07817 1/20 0.35
TP53 P04637 1/20 0.34
ALDH1A1 P00352 3/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182185 0.89 ALDH1A1 (0.38) KMT2AMEN1HPGDNPSR1LMNA
SCHEMBL7182634 0.88 LMNA (0.36) HPGDLMNABCL2L1ALDH1A1TDP1
SCHEMBL7180951 0.87 ALDH1A1 (0.34) KMT2AMEN1HPGDNPSR1LMNA
SCHEMBL7184532 0.86 TP53 (0.38) KMT2AMEN1RAB9ANPSR1LMNA
SCHEMBL7189208 0.86 TAS1R3 (0.35) KMT2AMEN1RAB9AHPGDNPSR1
SCHEMBL7188750 0.86 MEN1 (0.39) KMT2AMEN1RAB9AHPGDNPSR1
SCHEMBL7181100 0.84 TP53 (0.41) KMT2AMEN1RAB9AHPGDNPSR1
SCHEMBL7188524 0.83 KMT2A (0.38) KMT2AMEN1RAB9AHPGDNPSR1
SCHEMBL7180497 0.83 ALDH1A1 (0.41) LMNAALDH1A1ATMTDP1L3MBTL1
SCHEMBL7180036 0.81 KMT2A (0.37) KMT2AMEN1RAB9AHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885MEN1 2312/4885RAB9A 1818/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885MEN1 2263/4885RAB9A 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.